Indevus Announces FDA Approval of Sanctura® XR
Indevus Announces FDA Approval of Sanctura® XR
August 6, 2007 at 12:00 AM EDT
Indevus Announces FDA Approval of Sanctura® XR
August 6, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA).
CONTACT:
Russell "Rip" Wilson
Chief Financial Officer
Supernus Pharmaceuticals, Inc.
Tel: 301 838-2522
All trademarks are the property of their respective owners.